

S6 Table. Neurocognitive changes after concurrent chemoradiotherapy in prospective clinical studies

Objective	No. of initial participants	Follow-up period (mo)	SMD	95% CI	p-value
Couwenberg, LAR	134	3	-0.363	-0.543 to -0.185	< 0.001
Couwenberg, APR	119	3	-0.396	-0.592 to -0.201	< 0.001
Souza	29	3	0.389	-0.131 to 0.908	0.143
Bencova, men	43	N/A	-1.076	-1.529 to -0.623	< 0.001
Bencova, women	21	N/A	-0.066	-0.671 to 0.539	0.832
Total (I ² =79%)	346				
Fixed			-0.374	-0.494 to -0.253	<0.001
Random			-0.321	-0.776 to 0.133	0.165

APR, abdominoperineal resection; CI, confidence interval; LAR, low anterior resection; SMD, standardized mean difference.

References

1. Andreis F, Ferri M, Mazzocchi M, Meriggi F, Rizzi A, Rota L, et al. Lack of a chemobrain effect for adjuvant FOLFOX chemotherapy in colon cancer patients: a pilot study. *Support Care Cancer*. 2013;21:583-90.
2. Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. *J Clin Oncol*. 2015;33:4085-92.
3. Cruzado JA, Lopez-Santiago S, Martinez-Marin V, Jose-Moreno G, Custodio AB, Feliu J. Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. *Support Care Cancer*. 2014;22:1815-23.
4. Sales MVC, Suemoto CK, Apolinario D, Serrao V, Andrade CS, Conceicao DM, et al. Effects of adjuvant chemotherapy on cognitive function of patients with early-stage colorectal cancer. *Clin Colorectal Cancer*. 2019;18:19-27.
5. Anstey KJ, Sargent-Cox K, Cherbuin N, Sachdev PS. Self-reported history of chemotherapy and cognitive decline in adults aged 60 and older: the PATH Through Life Project. *J Gerontol A Biol Sci Med Sci*. 2015;70:729-35.
6. Lee SH, Lee TG, Baek MJ, Kim JJ, Park SS, Lee SJ. Quality of life changes during adjuvant chemotherapy in patients with colon cancer. *Korean J Clin Oncol*. 2016;12:60-6.
7. Tsunoda A, Nakao K, Watanabe M, Matsui N, Tsunoda Y. Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin. *Jpn J Clin Oncol*. 2010;40:412-9.